|Description||NVP-BSK805, a quinoxaline derivative, is a selective ATP-competitive JAK2 inhibitor which could induce apoptosis (GI50 < 100 nM) and restrain the growth of JAK2V617F cells (Ba/F3). IC50: 0.48 ± 0.02 nM (JAK2 JH1); 0.58 ± 0.03 nM (FL JAK2 wt).|
|Synonyms||NVPBSK805; NVP-BSK805; BSK805; BSK 805; 8-(3,5-DIFLUORO-4-(MORPHOLINOMETHYL)PHENYL)-2-(1-(PIPERIDIN-4-YL)-1H-PYRAZOL-4-YL)QUINOXALINE|
|Solubility||DMSO: 67 mg/mL; H2O: <1 mg/mL; EtOH: 7 mg/mL|
|Application||NVP-BSK805 is a selective ATP-competitive JAK2 inhibitor which could induce apoptosis and restrain the growth of JAK2V617F cells.|
|Shelf Life||As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly|
CEP-33779 is a highly selective, orally active, small-molecule inhibitor of JAK2. CEP-33779 induced regression of established colorectal tumors, reduced angioge...
Tofacitinib (trade name Xeljanz, formerly tasocitinib, CP-690550) is a drug discovered and developed by Pfizer. It is currently approved for the treatment of rh...
Pyridone 6 is a potent and selective inhibitor of JAK1, JAK2, JAK3, and Tyk2, displaying significantly weaker affinities for other protein tyrosine kinases. It ...
WP1066 is a Stat3 inhibitor and JAK2 inhibitor. WP1066 is also a novel analogue of the JAK2 inhibitor AG490, in JAK2 V617F-positive erythroleukemia HEL cells a...
Oclacitinib, also known as PF03394197, is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. Oclacitinib inhibited JAK family m...
Oclacitinib, also called as PF-03394197, is a novel inhibitor of JAK family members (IC50= 10 - 99 nM) and JAK1-dependent cytokines involved in allergy, inflamm...
Tofacitinib (CP-690550,Tasocitinib) is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.It is currently approved f...
Upadacitinib is a selective JAK inhibitor under the development of AbbVie.ABT-494 is nearly 74 fold selective for Jak1 over Jak2 in cellular assays dependent on...
Solcitinib, also known as GSK2586184 or GLPG0778, is a Janus kinase 1 (JAK1) inhibitor. Solcitinib may be potential useful for treatment of psoriasis, systemic ...
ZM 39923 inhibits Janus kinase (IC50=10 nM).
Cerdulatinib, also known as PRT2070 and PRT062070, is a novel, oral, dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor. Cerdulatinib preferenti...
CYT387 Mesylate is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, ~10-fold selectivity versus JAK3.
Gandotinib is a potent and selective JAK inhibitor, which effectively inhibited JAK2V617F-driven signaling and cell proliferation in Ba/F3 cells (IC50=20 and 55...
TCS 21311 is a potent JAK3 inhibitor (IC50 = 8 nM) with selectivity for JAK3 over JAK1, JAK2 and TYK2 (IC50 = 1017, 2550 and 8055 nM, respectively). It also inh...
NS-018, a selective JAK2 as well as Src family tyrosine kinases inhibitor that could probably induce the apoptosis of tumor cells. It is still under Phase I/II ...
CYT387 sulfate salt
CYT387 sulfate is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, ~10-fold selectivity versus JAK3.
Atiprimod dihydrochloride is the dihydrochloride salt form of atiprimod, which is an orally bioavailable small molecule belonging to the azaspirane class of cat...
ZM 39923 HCl
Selective inhibitor of Janus tyrosine kinase 3 (JAK3). pIC50 values are 7.1, 5.6, 4.4, and < 5.0 for JAK3, EGFR, JAK1 and CDK4 respectively. Breaks down in neut...
BBT594, also called as NVP-BBT594, a dihydroindole compound, originally developed as an inhibitor of wild-type and T315I-mutant BCR–ABL1, and then subsequently ...